Neurology Devices Market is Expected to Reach USD 22,335.5 Million by 2035, Growing at 6.7% CAGR

Market Overview - The global neurology devices market is projected to reach a valuation of USD 11,678 million in 2025, with an expected CAGR of 6.7% from 2025 to 2035 [1][8] - The market created an opportunity of USD 2,245 million growing at a CAGR of 5.9% between 2020 to 2025 [8] Neurological Disease Burden - Over 1 in 3 adults worldwide are affected by neurological diseases, making it the largest cause of disease and impairment globally [2] - From 1990 to 2021, the overall disability and early death due to neurological diseases rose by 18%, with 3.4 million people (43.1%) living with such conditions in 2021 [3] Technological Advancements - Continuous growth in neurology devices is attributed to the development of minimally invasive devices utilizing artificial intelligence for superior diagnosis and treatment [4] - Companies are innovating and forming strategic partnerships to enhance market dominance in response to the rising demand for improved neurological treatments [9] Market Drivers - The increasing prevalence of neurological disorders, such as Alzheimer's and Parkinson's diseases, is driving demand for treatment devices and diagnostic equipment [5] - The aging population is more vulnerable to neurological disorders, further increasing the demand for advanced neurology devices [5] Healthcare Spending and Accessibility - Rising healthcare spending in emerging economies is improving patient access to advanced neurology devices, supported by government initiatives and favorable reimbursement policies [6] Key Players and Innovations - Leading companies in the neurology devices market include Medtronic, Boston Scientific Corporation, Stryker Corporation, and Abbott Laboratories [9][17] - Significant investments in research and development are being made, such as Precision Neuroscience's funding of USD 102 million for brain-computer interface technology [11] Clinical Trials and New Technologies - A partnership between Amber Therapeutics and Oxford University conducted a clinical trial of Picostim, demonstrating an 80% reduction in seizures for neurological disorder treatment [12] - Inbrain Neuroelectronics introduced a brain implant made from graphene, aimed at improving outcomes in brain cancer surgeries and treating conditions like Parkinson's disease and epilepsy [13] Market Segmentation - The study categorizes the market based on device type, application (e.g., Alzheimer's, Parkinson's), and end user (e.g., hospitals, neurology clinics) across major global regions [15]